Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2065–2088 of 2,670 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: University of San Francisco Clear all

Conditions: HIV Infections
Interventions: Interruption of enfuvirtide, enfuvirtide interrupton; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Venous Thromboembolism
Interventions: Filter Placed; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatocellular Carcinoma, Chemoembolization
Interventions: LC Bead; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: diagnostic laboratory biomarker analysis, flow cytometry, physiologic testing, computed tomography; Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV -1 Infection
Interventions: Live Biotherapeutic Product L. jensenii 1153-1666, Placebo; Drug
Lead sponsor: Craig Cohen, MD, MPH; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Intracerebral Hemorrhage
Interventions: Statins; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 1,456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral T-Cell Lymphoma
Interventions: Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection, Granulocyte-colony stimulating factor (G-CSF), Pegfilgrastim, Cyclophosphamide, Vincristine, Leucovorin, Methotrexate, Doxorubicin Hydrochloride, Cytarabine, Etoposide, Carmustine, Denileukin diftitox; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hepatitis C, Chronic
Interventions: Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 64 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stress, Psychological
Interventions: Meditation; Behavioral
Lead sponsor: University of California, Riverside; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Riverside, California

Conditions: COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease, Coronavirus Infections, Pharyngeal Diseases
Interventions: Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash, Distilled water, Listerine Zero Mouthwash Product; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Nicotine Dependence
Interventions: Tobacco Cigarette, Electronic Cigarette; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Sepsis, Septic Shock, Severe Sepsis
Interventions: Severe Sepsis Prediction, Severe Sepsis Detection; Other
Lead sponsor: Dascena; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Mild Intellectual Disability, Borderline Intellectual Functioning
Interventions: D-kit/EF1, Sham group program; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 4 Years to 8 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis
Interventions: 4.5 mg Naltrexone, Naltrexone; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 86 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Known or Suspected Abdominal Disease
Interventions: Barium, Diatrizoate, Iohexol; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Adults
Interventions: Body-Brain Trainer, Body Trainer, Brain Trainer, Expectancy Matched Control; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neurocognitive Dysfunction
Interventions: Transseptal Aortic Approach Catheter Ablation Procedure, Retrograde Aortic Approach Catheter Ablation Procedure; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Pembrolizumab; Biological
Lead sponsor: Alfred Chung, MD; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypoxia
Interventions: BabySat V3; Device
Lead sponsor: Owlet Baby Care, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Endometriosis, Ovarian Hyperstimulation
Interventions: Placebo oral tablet, Letrozole; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Primary Aldosteronism Due to Conn Adenoma
Interventions: Unilateral adrenalectomy; Procedure
Lead sponsor: UMC Utrecht; Other
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Trauma, Psychological, Mental Disorder in Adolescence, Adolescent - Emotional Problem
Interventions: Fuerte; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years and older
Enrollment: 321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Colorectal Cancer
Interventions: Video-based terminal feedback; Behavioral
Lead sponsor: San Francisco Veterans Affairs Medical Center; Federal
Eligibility: 25 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Focus Groups
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

ODEN Trial: Option vs. Denali IVC Filters

TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve

Effect of Androgen Blockade Therapy on Thymus Function in Older Patients Who Have Undergone Radical Prostatectomy for Localized Prostate Cancer

Safety Study of MucoCept-CVN

Statins In Intracerbral Hemorrhage

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

Stress Free UCR: The Impact of 8 Weeks of Headspace on Stress in a Heterogeneous University Employee Cohort

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

Clinical Pharmacology of Electronic Cigarettes

An Algorithm Driven Sepsis Prediction Biomarker

Intervention Utilizing a Computerized Cognitive Rehabilitation Program (D-kit/EF1)

A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone

Uniformity of Oral Contrast Material in the Bowel

Characterizing the Synergistic Effects of Physical and Cognitive Training on Attention and Working Memory

Transseptal vs Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Accuracy of BabySat V3 With Profound Hypoxia and Motion

Assessment and Prevention of Pain During Ovarian Stimulation in Patients With Endometriosis

Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis

Fuerte Program for Newcomer Immigrant Youth

Improving Competency and Metrics for PoLypectomy Skills Using Evaluation Tools and VidEo Feedback (COMPLETE)

Study Of PHarmacogenetics in Ethnically Diverse Populations (SOPHIE Study)